Published in Bull Cancer on January 01, 1986
Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics (2012) 0.96
Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification. J Proteome Res (2012) 0.85
Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction. Br J Cancer (1991) 0.75
A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med (1995) 3.98
Gastric dysplasia: the Padova international classification. Am J Surg Pathol (2000) 3.66
Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology (1994) 3.15
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology (1997) 3.10
Long-term follow-up of achalasia patients treated with botulinum toxin. Dig Liver Dis (2002) 2.24
An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy (2006) 2.22
Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol (1996) 2.19
The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr Suppl (1996) 2.18
Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet (1992) 2.13
Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. Acta Paediatr (2000) 2.09
Porencephalic cyst after chorionic villus sampling. Prenat Diagn (1992) 2.02
Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther (2006) 2.00
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet (1999) 1.98
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc (2000) 1.97
Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther (2002) 1.94
Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology (2010) 1.88
Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol (2005) 1.85
Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci (2000) 1.71
Evidence for a multifactorial control of serum erythropoietin concentration in liver disease. Clin Chim Acta (1993) 1.69
Histological features after liver transplantation in alcoholic cirrhotics. J Hepatol (2001) 1.69
How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer (2000) 1.68
Neonatal anthropometric charts: what they are, what they are not. Arch Dis Child Fetal Neonatal Ed (2007) 1.66
Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. Eur J Gastroenterol Hepatol (2005) 1.64
Cardiac troponin I, cardiac troponin T and creatine kinase MB concentrations in umbilical cord blood of healthy term neonates. Acta Paediatr (2003) 1.64
Chronic atrophic gastritis and Helicobacter pylori infection in primary biliary cirrhosis: a cross-sectional study with matching. Ital J Gastroenterol Hepatol (1997) 1.63
Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis (2000) 1.62
Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut (2006) 1.61
Early versus late surgery for ileo-caecal Crohn's disease. Aliment Pharmacol Ther (2007) 1.60
Do varicose veins affect quality of life? Results of an international population-based study. J Vasc Surg (2001) 1.60
Oxidative DNA damage accumulation in gastric carcinogenesis. Gut (1998) 1.57
Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition (1997) 1.54
Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol (2000) 1.52
Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis. Clin Exp Immunol (1972) 1.50
Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig Liver Dis (2002) 1.50
High serum cardiac troponin T concentrations in preterm infants with respiratory distress syndrome. Acta Paediatr (2000) 1.50
Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut (2004) 1.50
A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. GISMAD Achalasia Study Group. Gut (2000) 1.48
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment Pharmacol Ther (2006) 1.48
Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol (1995) 1.48
Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig Liver Dis (2004) 1.46
Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Dig Liver Dis (2001) 1.46
Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN. J Gastroenterol (1999) 1.44
Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis (2003) 1.44
Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer (1999) 1.43
The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly. Eur J Gastroenterol Hepatol (1997) 1.42
Upper gastrointestinal injury caused by diquat. Gastrointest Endosc (1992) 1.41
Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol (1994) 1.40
Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers (2002) 1.40
Carbohydrate-induced thermogenesis in liver cirrhosis: glucose vs. fructose. Nutrition (1995) 1.39
Fasting hyperglycaemia following trans-catheter arterial chemo-embolization for hepatocellular carcinoma in cirrhosis. Ital J Gastroenterol Hepatol (1997) 1.39
Helicobacter pylori infection and growth delay in older children. Arch Dis Child (1997) 1.39
Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis. Cancer (1991) 1.39
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study). Dig Liver Dis (2000) 1.39
Strategies for the early diagnosis of acute myocardial infarction using biochemical markers. Am J Clin Pathol (1999) 1.38
Hormonal treatment of hepatocellular carcinoma. J Hepatol (1991) 1.38
Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol (1998) 1.37
Neutrophil NADPH oxidase activity in chronic myeloproliferative and myelodysplastic diseases by microscopic and photometric assays. Acta Haematol (1995) 1.37
The long term outcome of gastric non-invasive neoplasia. Gut (2003) 1.37
Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther (2008) 1.36
The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol (2000) 1.36
Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol (2000) 1.33
Hepatitis B virus infection in prisons. A seroepidemiological survey in prisoners and attending staff. J Hyg (Lond) (1982) 1.32
Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer (1999) 1.31
Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer (2003) 1.30
Immunological and histological studies in primary biliary cirrhosis. J Clin Pathol (1970) 1.29
Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology (1999) 1.29
Helicobacter pylori infection enhances mucosal interleukin-1 beta, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res (1996) 1.28
Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol (2000) 1.24
Helicobacter pylori babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. J Clin Pathol (2003) 1.23
Direct-to-consumer testing: more risks than opportunities. Int J Clin Pract (2011) 1.22
Quality of analytical performance in inherited metabolic disorders: the role of ERNDIM. J Inherit Metab Dis (2008) 1.22
Helicobacter pylori virulence genes and host IL-1RN and IL-1beta genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. Cytokine (2002) 1.20
Liver transplantation: the Italian experience. Dig Liver Dis (2002) 1.19
Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res (1995) 1.19
Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology (1995) 1.17
Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology (1998) 1.17
Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis (2003) 1.17
Case definitions for human poisonings postulated to palytoxins exposure. Toxicon (2011) 1.17
Perinatal transmission of the hepatitis B virus and of the HBV-associated delta agent from mothers to offspring in northern Italy. J Med Virol (1982) 1.16
Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol (2008) 1.16
Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. Int Angiol (1999) 1.16
A locally adaptive statistical procedure (LAP) to identify differentially expressed chromosomal regions. Bioinformatics (2006) 1.16
Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Am Rev Respir Dis (1987) 1.16
Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther (2010) 1.15
Length of sedimentation reaction in undiluted blood (erythrocyte sedimentation rate): variations with sex and age and reference limits. Clin Chem Lab Med (2001) 1.15
Analysis of Helicobacter pylori vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases. Gut (1998) 1.14
Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer (1995) 1.13
The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res (1996) 1.13
Role of anti-transglutaminase (anti-tTG), anti-gliadin, and anti-endomysium serum antibodies in diagnosing celiac disease: a comparison of four different commercial kits for anti-tTG determination. J Clin Lab Anal (2001) 1.13